Juul M. Cox

Juul M. Cox

Auto-generated profile, based on publicly available information

Juul M. Cox

Department of Hospital Pharmacy, Maasstad Hospital, Rotterdam, The Netherlands

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 March 2021 in British Journal of Cancer
Verified
Journal Article
Closed access
PDF file
JCJuul M. Cox
Juul M. Cox
LDLeni van Doorn
Leni van Doorn
RMRuben Malmberg
Ruben Malmberg
EHEsther Oomen-De Hoop
Esther Oomen-De Hoop
TBTessa M. Bosch
Tessa M. Bosch
RLRoelof W. F. van Leeuwen
Roelof W. F. van Leeuwen

9 July 2023 in Annals of the Rheumatic Diseases
Verified
Journal Article
Closed access
PDF file
LELuuk van Esveld
Luuk van Esveld
JCJuul M Cox
Juul M Cox
TKT Martijn Kuijper
T Martijn Kuijper
TBTessa M Bosch
Tessa M Bosch
AWAngelique Weel
Angelique Weel
Objectives Current guidelines recommend tapering biological disease-modifying antirheumatoid drugs (bDMARDs) in rheumatoid arthritis (RA) if the disease is under control. However, guidelines on tapering are lacking. Assessing cost-effectiveness of different tapering strategies might provide broader input for creating guidelines on how to taper bDMARDs in patients with RA. The aim of this study is to evaluate the long-term cost-effectiveness from a societal perspective of bDMARD tapering strategies in Dutch patients with RA, namely 50% dose reduction (tapering), discontinuation and a 50% dose reduction followed by discontinuation (de-escalation). Methods Using a societal perspective, a Markov model with a life-time horizon of 30 years was used to simulate 3-monthly transitions between Disease Activity 28 (DAS28)-defined health states of remission (<2.6), low disease activity (2.6<DAS28<3.2) and medium-high disease activity (DAS28>3.2). Transition probabilities were estimated through literature search and random effects pooling. Incremental costs, incremental quality-adjusted life-years (QALYs), incremental cost-effectiveness ratios (ICERs) and incremental net monetary benefits for each tapering strategy were compared with continuation. Deterministic, probabilistic sensitivity analyses and multiple scenario analyses were performed. Results After 30 years, the ICERs were €115 157/QALY lost, €74 226/QALY lost and €67 137/QALY lost for tapering, de-escalation and discontinuation, respectively; mainly driven by bDMARD cost savings and a 72.8% probability of a loss in quality of life. This corresponds to a 76.1%, 64.3% and 60.1% probability of tapering, de-escalation and discontinuation being cost-effective, provided a willingness-to-accept threshold of €50 000/QALY lost. Conclusions Based on these analyses, the 50% tapering approach saved the highest cost per QALY lost.

1 September 2024 in JCO Oncology Practice
Verified
Journal Article
Closed access
RMRuben Malmberg
Ruben Malmberg
Leni van DoornLeni van Doorn
Leni van Doorn
JCJuul M. Cox
Juul M. Cox
ADAlaa Daloul
Alaa Daloul
HEHalima Ettafahi
Halima Ettafahi
RLRoelof W.F. van Leeuwen
Roelof W.F. van Leeuwen
PURPOSE: Premedication, including a histamine-1 receptor (H1) antagonist, is recommended to all patients treated with paclitaxel chemotherapy to reduce the incidence of hypersensitivity reactions (HSRs). However, the scientific basis for this premedication is not robust, which provides opportunities for optimization. Substitution of intravenously administered first-generation H1 antagonist for orally administered second-generation H1 antagonist could reduce side effects, and improve efficiency and sustainability. This study investigates the efficacy and safety of substituting intravenous clemastine for oral cetirizine as prophylaxis for paclitaxel-induced HSRs. METHODS: This single-center, prospective, noninferiority study compares a historic cohort receiving a premedication regimen with intravenous clemastine to a prospective cohort receiving oral cetirizine. Primary end point of the study is HSR grade ≥3. The difference in incidence was calculated together with the 90% CI. We determined that the two-sided 90% CI of HSR grade ≥3 incidence in the oral cetirizine cohort should not be more than 4% higher (ie, the noninferiority margin) compared with the intravenous clemastine cohort. RESULTS: Two hundred and twelve patients were included in the oral cetirizine cohort (June 2022 and May 2023) and 183 in the intravenous clemastine cohort. HSR grade ≥3 incidence was 1.6% (n = 3) in the intravenous clemastine cohort and 0.5% (n = 1) in the oral cetirizine cohort, resulting in a difference of –1.2% (90% CI, –3.4 to 1.1). CONCLUSION: Premedication containing oral cetirizine is as safe as premedication containing intravenous clemastine in preventing paclitaxel-induced HSR grade ≥3. These findings could contribute to optimization of care for patients and improve efficiency and sustainability.

21 August 2025 in Therapeutic Drug Monitoring
Verified
Journal Article
Closed access
JCJuul M. Cox
Juul M. Cox
HAHazar El Achaouch
Hazar El Achaouch
TKT. Martijn Kuijper
T. Martijn Kuijper
AWAngelique Weel
Angelique Weel
TBTessa M. Bosch
Tessa M. Bosch
Background: The association between adalimumab trough levels and disease activity was evaluated in a real-world population with rheumatoid arthritis (RA). The distribution of adalimumab serum levels, proportion of patients with therapeutic exposure to adalimumab, and the presence of antidrug antibodies (ADAs) were explored to determine the utility of therapeutic drug monitoring in RA. Methods: A cross-sectional study was conducted among 72 patients with RA who were treated with adalimumab at Maasstad Hospital between May 2022 and March 2023. The adalimumab trough levels and ADAs were measured at the steady state. Disease activity was assessed using the using the Disease Activity Score-28 based on C-reactive protein (DAS28-CRP). Univariable and multivariable regression analyses were conducted to examine the associations between adalimumab levels, disease activity, and clinical covariates, including sex, body mass index, and concomitant methotrexate use. Results: The interindividual variability in the adalimumab trough levels was wide (range: 1.2–16 mcg/mL; median: 5.9 mcg/mL). No significant association was observed between the adalimumab trough levels and DAS28-CRP scores ( P > 0.05). ADAs were present in 13.9% of the patients, and the drug levels were undetectable in 4.2%. The adalimumab trough levels were considerably higher in women than in men ( P < 0.05), whereas extended dosing intervals were associated with lower adalimumab concentrations but not with higher disease activity. Conclusions: The variability in adalimumab exposure is wide in patients with RA. However, no clear association was observed between adalimumab exposure and disease activity. These findings suggest that therapeutic drug monitoring aids in identifying patients with underexposure or overexposure to adalimumab and support individualized dose optimization, particularly in patients with low disease activity. Future prospective studies are required to evaluate the longitudinal effects of TDM-guided strategies.

3 August 2026 in Critical Care Explorations
Verified
Journal Article
Open access
JCJuul M. Cox
Juul M. Cox
JVJulia A. M. Verwaaijen
Julia A. M. Verwaaijen
RHRuben M. F. Hendriks
Ruben M. F. Hendriks
DSDorien Smeets
Dorien Smeets
SRSuzanne van Rijswijk
Suzanne van Rijswijk
TBTessa M. Bosch
Tessa M. Bosch
BACKGROUND: Severe intoxication with nondihydropyridine calcium channel blockers, such as diltiazem, is associated with high morbidity and mortality. Evidence supporting extracorporeal treatment strategies remains limited. This case integrates serial toxicokinetic measurements with adjunctive hemoadsorption in sustained-release diltiazem poisoning. CASE SUMMARY: A 73-year-old man presented with coma, complete atrioventricular block, refractory hypotension, and severe lactic acidosis. Despite optimized supportive therapy including vasopressors, calcium supplementation, hyperinsulinemic-euglycemic therapy, and continuous renal replacement therapy, he remained hemodynamically unstable. CytoSorb hemoadsorption was initiated 6 hours after ICU admission. Shortly thereafter, sinus rhythm was restored, serum lactate rapidly declined, and vasopressor and insulin requirements were progressively reduced, allowing discontinuation of extracorporeal support. The patient recovered and was discharged home. CONCLUSIONS: Retrospective analysis demonstrated elevated diltiazem concentrations with delayed, capacity-limited elimination. This case supports considering hemoadsorption in unstable patients with severe diltiazem poisoning despite conventional measures and highlights the need for systematic pharmacokinetic evaluation in future studies.